國家衛生研究院 NHRI:Item 3990099045/13302
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 954912      線上人數 : 603
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/13302


    題名: Beta-glucan therapy converts the inhibition of myeloid-derived suppressor cells in oral cancer patients
    其他題名: β-glucan therapy converts the inhibition of myeloid-derived suppressor cells in oral cancer patients
    作者: Lo, YW;Lee, AY;Liu, YC;Ko, HH;Peng, HH;Lee, HC;Pan, PY;Chiang, CP;Cheng, SJ
    貢獻者: National Institute of Cancer Research
    摘要: OBJECTIVES: The myeloid-derived suppressor cells (MDSCs) frequently have a high expansion in cancer patients. This research explored whether administration of β-glucan could increase anti-tumor immunity in oral squamous cell carcinoma (OSCC) patients. MATERIALS AND METHODS: This study evaluated the MDSC level of circulating blood as CD33(+) /CD11b(+) /HLA-DR(-/low) by flow cytometry in 30 healthy donors (HDs, group I), in 48 oral squamous cell carcinoma (OSCC) patients before and after 14-day pre-operative administration of β-glucan (group II), and in 52 OSCC patients without taking β-glucan (group III). RESULTS: A significantly higher mean MDSC level was observed in 100 OSCC patients than in 30 HDs (p < 0.001). There was a significant reduction of the mean MDSC level in group II patients after taking β-glucan (p < 0.001). Moreover, we discovered a significantly higher recurrence-free survival (RFS) in group II than in group III patients (p = 0.026). Finally, the multivariate Cox regression further identified the MDSC level ≤ 1% and administration of β-glucan as more favorable prognostic factors for OSCC patients. CONCLUSION: Preoperative administration of β-glucan can augment anti-tumor immunity and increase RFS rate via subversion of suppressive function of MDSC in OSCC patients.
    日期: 2022-09
    關聯: Oral Diseases. 2022 Sep;28(6):1484-149.
    Link to: http://dx.doi.org/10.1111/odi.13827
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1354-523X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000628452300001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85102475600
    顯示於類別:[李岳倫] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB33655573.pdf2321KbAdobe PDF314檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋